Hypofractionated salvage radiotherapy did not improve biochemical control after prostatectomy
Four-year biochemical control was similar with 65 Gy in 26 fractions and 66 Gy in 33 fractions, while gastrointestinal toxicity was higher.
Tag
prostate
AI supported an MRI-only prostate planning workflow with near-identical dose calculation
AI-generated synthetic CT achieved 99.8% gamma agreement with conventional CT while automated pelvic contours remained within expert interobserver variability.
Whole-pelvic radiotherapy did not improve survival in high-risk node-negative prostate cancer
Across five phase III trials, whole-pelvic radiotherapy did not improve overall survival, and progression benefits disappeared when POP-RT was excluded.
Salvage HDR brachytherapy had low severe toxicity but limited five-year biochemical control
Five-year PSA progression-free survival was 24.8% after two-fraction salvage HDR brachytherapy without androgen deprivation, despite low severe toxicity.
Most salvage prostate radiotherapy plans met SPPORT and RADICALS-HD dose constraints
Most multicenter salvage prostate radiotherapy plans met SPPORT and RADICALS-HD organ constraints, with smaller bladder volumes linked to more violations.
Carbon ions produced more persistent tumor damage but hypoxic cells showed late rebound
Carbon ions prolonged tumor-cell damage while chronic hypoxia supported late proliferative and macrophage rebound in rat prostate tumors.
Early PSA-density kinetics after prostate SABR identified patients at high recurrence risk
Combining ISUP grade with 3–6-month PSA-density kinetics separated seven-year biochemical control at 93.5% versus 53.4% after SABR without ADT.
Treatment satisfaction remained 85% at ten years after prostate LDR brachytherapy
At ten years after prostate LDR brachytherapy, 85% of respondents remained satisfied, while bowel quality of life remained independently associated with satisfaction.
Five-fraction prostate and pelvic SABR showed durable control with low late toxicity
Five weekly SABR fractions to prostate and pelvic nodes produced 10.5% five-year biochemical failure with low persistent gastrointestinal and urinary toxicity.
AI biomarker substantially reduced planned ADT use in intermediate-risk prostate cancer
ASTuTE biomarker testing changed 27.5% of shared decisions and reduced planned short-term ADT use from 37% to 12.5%.
Rectal spacer geometry remained stable throughout five-fraction prostate SBRT
Hydrogel spacers showed no meaningful loss of geometry during prostate SBRT, supporting stable rectal separation across the treatment course.
Prostate target expansion identified fractions most likely to benefit from online re-optimization
Without online re-optimization, 65.3% of prostate fractions missed 95% target coverage, with later target expansion strongly linked to coverage loss.
Deep learning-enhanced registration halves contouring time in daily adaptive prostate MRgRT
A hybrid deep learning–registration workflow reduced median daily prostate MRgRT contouring time from 7.8 to 3.1 minutes while maintaining high contour agreement.
LncDNAH5 linked a prostate radiotoxicity risk variant to altered DNA repair
The rs7720298 risk allele increased LncDNAH5 expression, promoting TP53BP1 degradation and worsening radiation-induced bladder injury in mice.
Empty-bladder prostate SBRT met the EMPTY-RT acute safety endpoint
Empty-bladder SBRT was feasible in 85% of screened patients, with grade 2 or higher urinary toxicity of 28.1%.